From Wuhan China — promising results have just been published in a preliminary report by Dr. Zhong Yangling for the treatment of 5 COVID-19 patients (2 of which were critical and 3 were severe) with hyperbaric therapy at the Department of Hyperbaric Oxygen in Wuhan Yangtze River Shipping General Hospital. In this report, hyperbaric oxygen was added to the current comprehensive treatments being performed at the hospital for COVID-19 affected patients, with a dose of 90-120 minutes at treatment pressures of 1.4 to 1.6 ATA. The results were very encouraging as these 5 patients received significant therapeutic benefits, including rapid relief of symptoms after the first session. The rationale for adding this procedure is to help combat the progressive hypoxemia (low blood oxygen levels) that COVID-19 can cause. Hyperbaric oxygen has the ability to add a substantial supply of extra oxygen into the bloodstream and therefore can help during these times of hypoxemia. Hypoxemia is the key determinant to the deterioration of patients seen with COVID-19. The virus attacks the lungs and causes inflammation and the body has a difficult time getting enough oxygen transferred from the lungs into the body. This progressive hypoxemia leads to the increase in mortality rates as patients can become critically ill. At this time, they are typically in compete reliance on ventilators to help restore oxygen levels, to keep them alive, while the body fights the virus and repairs the lung damage. Advantages of hyperbaric oxygen for treatment of progressive hypoxemia is that the higher pressure environment allows greater levels of oxygen to pass through the thickened and inflamed lung tissue into the blood stream; thereby directly treating the hypoxemia. Add to this, the greater solubility of oxygen in the blood (in hyperbaric conditions) and it’s now easy to see why all 5 patients reported dramatic relief of their symptoms — Dr. Zhong reported that after the first session of hyperbaric oxygen, symptoms such as dyspnea (shortness of breath) and chest pain were reduced. After the second session, the respiratory rate decreased gradually and the shortness of breath (after movement) relieved slowly. To correlate with these subjective results, Dr. Zhong was able to objectively chart a significant upward trend of oxygen levels, day by day. In addition, lung inflammation was re-evaluated though CT scan and all 5 patients significantly improved. It should be noted, that hyperbaric oxygen is not a treatment for the COVID-19 virus and this report should NOT lead people to look for hyperbaric chambers for treating the virus, particulary within private centers that are not equipped for treating infectious diseases. However, this is a very important paper outlining the potential clinical role that hyperbaric therapy can play in the symptomatic relief of hypoxemia that is seen in the COVID-19 affected population. Hopefully, this will lead the medical community to take a much harder look at integrating hyperbaric therapy and utilizing its key physiological benefits (ie, reducing hypoxia). In turn, this could lead to a much larger demand for the use of hyperbaric chambers in hospitals and infectious disease centers to coexist as supportive therapy, during these critical stages. Deploying hyperbaric chambers in this manner could offer a major lifeline support to patients, while aggressive medical treatments are being administered in the hospital setting. This applies to both current hospital-type chambers and portable hyperbaric chambers as these chambers can be performed in the open area of the hospital. Hospital chambers — According to Dr. Zhong, these chambers can help “improve the treatment efficiency, reduce the medical pressure and the risk of infection, and decrease the mortality rate of critical patients”. With the limited supply of ventilators, hyperbaric chambers can offer valuable relief. Hyperbaric Oxygen Department of Wuhan Changjiang Shipping General Hospital has established a complete infection control procedures and measures for hyperbaric treatment of patients with coronavirus. If followed, this could lead to a widespread movement of hyperbaric chambers to help in areas where the local demand is too great from community infection. In Wuhan, Huoshenshan hospitals are not equipped with hyperbaric chambers so construction of a new hyperbaric oxygen chamber system started at Huoshenshan Hospital and is being installed and commissioned for use within 15 days! Portable chambers — These chambers are typically operated at lower pressures of 1.3 ATA and can have physiological benefits in reducing hypoxemia. Of note, Dr. Zhong also tested 1.2 to 1.4 ATA and found that the oxygen levels were still kept in a high level and this was even with ambient air application. Again, as a supportive therapy, this could be very valuable for helping to maintain oxygen levels. Here in the United States, these types of chambers have been making steady growth in the hyperbaric industry (over the past 20 years) and fueled lately by high profile athletes promoting its benefits. As this industry grows, many private hyperbaric centers are now writing prescriptions for patients for home use. This may help during times of isolation and the early infection period where patients are told to stay at home until symptoms become severe and hypoxemia begins to take its toll. To summarize, this publication by Dr. Zhong should encourage us to look into hyperbaric medicine in a new way, when it comes to severe respiratory diseases caused by coronavirus. Since this study, Dr. Zhong has now treated a total of 35 COVID-19 cases. As this pandemic continues, we do not know how much of the public will be affected and the extra load that will impact our medical system. What we do know is that this virus primarily targets the lung tissue, causing severe inflammation and hypoxemia. Hyperbaric oxygen may offer a valuable therapeutic delivery of oxygenation during times of hypoxemia. More research should be looked into this. Dsiclaimer -- is very important that this article is not construed as an article that promotes treating COVID-19 with hyperbaric therapy. Anyone who has been diagnosed with COVID-19 or suspected of having this infection , should follow the CDC guidelines (and not seek treatments in a hyperbaric chamber as an alternative). This is purely educational material on the new preliminary report published from Wuhan China <view report> Read Less

The Neurobiology of Aging has just published a study supporting the use of hyperbaric oxygen therapy (HBOT) for Alzheimer’s disease (AD). In this study, they demonstrated the positive impact of HBOT on many of the commonly-found underlying pathologies that are observed in the AD brain. A key focus of this study was on HBOT’s ability to basically halt and reverse the neuro-inflammatory disease progression involved in AD <view study> Read Less

Osteoarthritis (OA) is a condition that is very common amongst the elderly and one that, for many, negatively affects their quality of life by causing a great deal of debility, and causing a dependency on pain medications (NSAIDS). OA is basically a degenerative condition of the joints whereby inflammatory markers seem to be the most important mediators of this cartilage destruction. Keep in mind that cartilage is able to repair itself through the induction of local growth factors, leading to the production of new collagen. This 'regenerative' repair is counteracted by the continual destruction seen with this disorder, leading to a progressive degenerative state. Since HBOT is considered to be a regenerative therapy, it would make sense that HBOT could help with a degenerative condition like OA. HBOT is already being used by OA sufferers for its anti-inflammatory pain-relieving effects, but now this study gives us insights on its potential long term benefits on reducing the net destruction and degeneration observed in OA. Researches were able to show that HBOT can benefit OA by helping with both factors that are involved in this disease. Firstly, HBOT caused a marked reduction of the key inflammatory markers involved this condition; thereby, reducing further degeneration. Secondly, HBOT caused an increase in the number of growth factors involved in the production of new collagen and cartilage formation, thus helping in the repair and regeneration of this tissue. The clinical relevance of this study is enormous, as it may offer OA sufferers the ability to counteract the degradative forces involved in OA, while still offering its pain-relieving benefits <view study> Read Less

This study clearly demonstrated that it only took 5 days to significantly enhance bone growth, reduce inflammation, and accelerate bone healing, with positive results in bone new bone formation <view study> Read Less

Long-term disabilities from spinal cord injuries are linked with the extent of secondary injury from the inflammation that immediately follows the injury. This natural body body response of inflammation, limits the amount of blood and oxygen getting to the area, and thus poses greater problem. Hyperbaric oxygen has been used as an off-label treatment for spinal cord injuries for many years now, with many positive reports by both patients and treating physicians. This study showed that applying hyperbaric therapy may reduce secondary damage by reducing the inflammatory factors produced by the body. This gives good rationale for using HBOT following spinal cord injuries, not only to reduce secondary damage due to inflammation, but for also getting extra oxygen into the area and promote further repair, while not losing functional capacity <view study> Read Less